Episomal Vector Blood Reprogramming Genomic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) from somatic cells face challenges such as invasive procedures, genomic instability, and high mutation rates, particularly when using fibroblasts, which are not ideal for clinical applications due to environmental insults and prolonged culture requirements.
Innovation Solution
A method involving the use of non-integrating episomal plasmid vectors to reprogram blood cells, specifically peripheral blood mononuclear cells (PBMCs), using reprogramming factors like Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40 Large T Antigen, and shRNA-p53, encoded in oriP/EBNA1 vectors, cultured on treated cell surfaces with extracellular matrix proteins like laminin, and maintained in specific media conditions to achieve stable and efficient iPSC generation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If fibroblasts are used as the starting material for reprogramming, then reprogramming can be performed, but the procedure becomes invasive and the cells accumulate mutations due to environmental insults
Solution Approach 1:
The invention changes the cell source parameter from fibroblasts (skin biopsy) to blood cells (peripheral blood draw), fundamentally altering the starting material to eliminate exposure to environmental insults while maintaining reprogramming capability. This parameter change resolves the contradiction by selecting a cell type that is both easily accessible and genetically stable.
2Productivity
If fibroblasts are used for reprogramming, then iPSCs can be generated, but the procedure requires prolonged culture expansion which increases time and complexity
Solution Approach 1:
The invention performs preliminary expansion of blood cells in culture before reprogramming, allowing the cells to be prepared and validated in advance. This preliminary action optimizes cell quality and quantity before the actual reprogramming process, reducing overall time loss and improving efficiency by ensuring cells are in the optimal state for reprogramming.
3Productivity
If integrating vectors are used for reprogramming, then reprogramming efficiency is high, but genomic stability is compromised due to vector integration
Solution Approach 1:
The invention uses non-integrating episomal vectors as an intermediary carrier for reprogramming factors. These vectors temporarily deliver the necessary transcription factors (Oct4, Sox2, Klf4, c-Myc) without integrating into the host genome, thus maintaining genomic stability while achieving sufficient reprogramming efficiency. The episomal vectors act as a temporary mediator that can be removed after reprogramming.
4Stability of the object's composition
If blood cells are used as the source, then genomic stability is improved, but the reprogramming protocol complexity increases
Solution Approach 1:
The invention segments the reprogramming protocol into distinct phases: blood cell isolation and expansion, transfection with episomal vectors, reprogramming culture, and iPSC colony formation. This segmentation allows each step to be optimized and controlled independently, reducing overall protocol complexity while maintaining the genomic stability benefits of using blood cells.
Data Source
AI summary
Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.